WallStreetZenWallStreetZen

NASDAQ: ASRT
Assertio Holdings Inc Stock Forecast, Predictions & Price Target

Analyst price target for ASRT

Based on 2 analysts offering 12 month price targets for Assertio Holdings Inc.
Min Forecast
$3.00+276.88%
Avg Forecast
$3.50+339.7%
Max Forecast
$4.00+402.51%

Should I buy or sell ASRT stock?

Based on 2 analysts offering ratings for Assertio Holdings Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ASRT stock forecasts and price targets.

ASRT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-12
lockedlocked$00.00+00.00%2023-11-03

1 of 1

Forecast return on equity

Is ASRT forecast to generate an efficient return?
Company
N/A
Industry
25.21%
Market
29.43%

Forecast return on assets

Is ASRT forecast to generate an efficient return on assets?
Company
N/A
Industry
13.24%

ASRT revenue forecast

What is ASRT's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$118.2M-22.27%
Avg 2 year Forecast
$136.2M-10.44%
ASRT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ASRT revenue growth forecast

How is ASRT forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?
Company
-22.27%
Industry
13.63%
Market
13.75%
ASRT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ASRT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ASRT vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
ASRT$0.80$3.50+339.70%Strong Buy
DERM$3.80$8.50+123.68%Strong Buy
ETON$3.19$10.00+213.48%Buy
EGRX$4.69N/AN/A
SCYX$1.41N/AN/A

Assertio Holdings Stock Forecast FAQ

Is Assertio Holdings Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ASRT) stock is to Strong Buy ASRT stock.

Out of 2 analysts, 1 (50%) are recommending ASRT as a Strong Buy, 1 (50%) are recommending ASRT as a Buy, 0 (0%) are recommending ASRT as a Hold, 0 (0%) are recommending ASRT as a Sell, and 0 (0%) are recommending ASRT as a Strong Sell.

If you're new to stock investing, here's how to buy Assertio Holdings stock.

What is ASRT's revenue growth forecast for 2024-2025?

(NASDAQ: ASRT) Assertio Holdings's forecast annual revenue growth rate of -22.27% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 13.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.

Assertio Holdings's revenue in 2024 is $152,069,000.On average, 1 Wall Street analysts forecast ASRT's revenue for 2024 to be $11,228,506,279, with the lowest ASRT revenue forecast at $11,228,506,279, and the highest ASRT revenue forecast at $11,228,506,279.

In 2025, ASRT is forecast to generate $12,938,431,093 in revenue, with the lowest revenue forecast at $12,938,431,093 and the highest revenue forecast at $12,938,431,093.

What is ASRT's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: ASRT) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 13.24%.

What is ASRT's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ASRT price target, the average ASRT price target is $3.50, with the highest ASRT stock price forecast at $4.00 and the lowest ASRT stock price forecast at $3.00.

On average, Wall Street analysts predict that Assertio Holdings's share price could reach $3.50 by Mar 12, 2025. The average Assertio Holdings stock price prediction forecasts a potential upside of 339.7% from the current ASRT share price of $0.80.

What is ASRT's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: ASRT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.